Daniel P. Petrylak, MD, presented “Phase 1 Trial of ARV-110 in Patients with mCRPC” for the Grand Rounds in Urology audience in June, 2020.
How to cite: Petrylak, Daniel P. “Phase 1 Trial of ARV-110 in Patients with mCRPC” June, 2020. Accessed Nov 2024. https://grandroundsinurology.com/phase-1-trial-of-arv-110-in-patients-with-mcrpc/
Phase 1 Trial of ARV-110 in Patients with mCRPC – Summary:
Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center, discusses promising new developments coming out of a trial that interferes with the androgen receptor and degrades it. Phase 1 of this trial looks at ARV-110 in patients with mCRPC and Dr. Petrylak highlights why the study’s recent findings are so exciting. He goes into detail the study methodology and how ARV-110 works in comparison to traditional treatments. Dr. Petrylak also explains why the findings are so promising and what the next steps are for the study.
To expand your knowledge of androgen deprivation therapy, visit our ADT Next Generation Learning Center.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, leads the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the genitourinary cancer research group, professor, and co-director of the Cancer Signaling Network program. Dr. Petrylak joined Yale from Herbert Irving Cancer Center at Columbia University Medical Center with New York-Presbyterian Hospital, where he served as Professor of Medicine (Medical Oncology) and Urology and began his appointment in September of 2012. After serving for more than 20 years as the advanced bladder chair for SWOG, Dr. Petrylak is now the Vice Chair of the Genitourinary Committee.
